Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer

Pharmacology and Therapeutics

Volumn 143, Issue 3, 2014, Pages 337-349

  Nisa, Lluís ^a,b   Aebersold, Daniel Matthias ^a,b   Giger, Roland ^a   Zimmer, Yitzhak ^a,b   Medová, Michaela ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Head and neck cancer; MET receptor tyrosine kinase; Prognostic impact; Targeted therapy; Treatment resistance

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; DISTANT METASTASIS; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR UPREGULATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; HEAD AND NECK NEOPLASMS; METABOLISM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84905277121     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.04.005     Document Type: Review

References (171)

1. T. Ach, K. Zeitler, S. Schwarz-Furlan, K. Baader, A. Agaimy, and C. Rohrmeier et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer Virchows Arch 462 2013 65 72
2. D.M. Aebersold, A. Kollar, K.T. Beer, J. Laissue, R.H. Greiner, and V. Djonov Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation Int J Cancer 96 2001 41 54
3. D.M. Aebersold, O. Landt, S. Berthou, G. Gruber, K.T. Beer, and R.H. Greiner et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx Oncogene 22 2003 8519 8523
4. J. Akervall, X. Guo, C.N. Qian, J. Schoumans, B. Leeser, and E. Kort et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients Clin Cancer Res 10 2004 8204 8213
5. A.E. Albers, C. Chen, B. Koberle, X. Qian, J.P. Klussmann, and B. Wollenberg et al. Stem cells in squamous head and neck cancer Crit Rev Oncol Hematol 81 2012 224 240
6. N.A. Andrews, A.S. Jones, T.R. Helliwell, and A.R. Kinsella Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases Br J Cancer 75 1997 1474 1480
7. A. Argiris, M.V. Karamouzis, D. Raben, and R.L. Ferris Head and neck cancer Lancet 371 2008 1695 1709
8. D. Bandyopadhyay, M. Mandal, L. Adam, J. Mendelsohn, and R. Kumar Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells J Biol Chem 273 1998 1568 1573
9. S. Berthou, D.M. Aebersold, L.S. Schmidt, D. Stroka, C. Heigl, and B. Streit et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 23 2004 5387 5393
10. V. Bhardwaj, Y. Zhan, M.A. Cortez, K.K. Ang, D. Molkentine, and A. Munshi et al. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression J Thorac Oncol 7 2012 1211 1217
11. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925
12. G.R. Blumenschein Jr., G.B. Mills, and A.M. Gonzalez-Angulo Targeting the hepatocyte growth factor-cMET axis in cancer therapy J Clin Oncol 30 2012 3287 3296
13. C. Boccaccio, and P.M. Comoglio Invasive growth: a MET-driven genetic programme for cancer and stem cells Nat Rev Cancer 6 2006 637 645
14. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
15. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
16. D.P. Bottaro, J.S. Rubin, D.L. Faletto, A.M. Chan, T.E. Kmiecik, and G.F. Vande Woude et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 251 1991 802 804
17. H. Brantjes, N. Barker, J. van Es, and H. Clevers TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling Biol Chem 383 2002 255 261
18. B.E. Brockstein Management of recurrent head and neck cancer: recent progress and future directions Drugs 71 2011 1551 1559
19. M.A. Broglie, S.K. Haerle, G.F. Huber, S.R. Haile, and S.J. Stoeckli Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival Head Neck 35 2013 660 666
20. I.J. Brusevold, T.M. Soland, C. Khuu, T. Christoffersen, and M. Bryne Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model Eur J Oral Sci 118 2010 342 349
21. B. Burtness, J.E. Bauman, and T. Galloway Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition Lancet Oncol 14 2013 e302 e309
22. K.M. Cai, X.L. Bao, X.H. Kong, W. Jinag, M.R. Mao, and J.S. Chu et al. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met Int J Mol Sci 25 2010 565 571
23. Y.C. Chen, Y.W. Chen, H.S. Hsu, L.M. Tseng, P.I. Huang, and K.H. Lu et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer Biochem Biophys Res Commun 385 2009 307 313
24. Y.S. Chen, J.T. Wang, Y.F. Chang, B.Y. Liu, Y.P. Wang, and A. Sun et al. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan J Oral Pathol Med 33 2004 209 217
25. C. Chen, M. Zimmermann, I. Tinhofer, A.M. Kaufmann, and A.E. Albers Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma Cancer Lett 338 2013 47 56
26. S.B. Chinn, O.A. Darr, R.D. Peters, and M.E. Prince The role of head and neck squamous cell carcinoma cancer stem cells in tumorigenesis, metastasis, and treatment failure Front Endocrinol 3 2012 90 (Lausanne)
27. J.Y. Choe, J.Y. Yun, S.J. Nam, and J.E. Kim Expression of c-Met is different along the location and associated with lymph node metastasis of head and neck carcinoma Korean J Pathol 46 2012 515 522
28. D.M. Cognetti, R.S. Weber, and S.Y. Lai Head and neck cancer: an evolving treatment paradigm Cancer 113 2008 1911 1932
29. P.M. Comoglio, and C. Boccaccio Scatter factors and invasive growth Semin Cancer Biol 11 2001 153 165
30. G. Cortesina, T. Martone, E. Galeazzi, M. Olivero, A. De Stefani, and M. Bussi et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases Int J Cancer 89 2000 286 292
31. F. De Bacco, P. Luraghi, E. Medico, G. Reato, F. Girolami, and T. Perera et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer J Natl Cancer Inst 103 2011 645 661
32. R. de Bree, E.E. Deurloo, G.B. Snow, and C.R. Leemans Screening for distant metastases in patients with head and neck cancer Laryngoscope 110 2000 397 401
33. M.J. De Herdt, and R.J. Baatenburg de Jong HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma Front Biosci 13 2008 2516 2526
34. M.F. Di Renzo, M. Olivero, T. Martone, A. Maffe, P. Maggiora, and A.D. Stefani et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas Oncogene 19 2000 1547 1555
35. G. Dong, Z. Chen, Z.Y. Li, N.T. Yeh, C.C. Bancroft, and C. Van Waes Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma Cancer Res 61 2001 5911 5918
36. C.H. Druzgal, Z. Chen, N.T. Yeh, G.R. Thomas, F.G. Ondrey, and D.C. Duffey et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma Head Neck 27 2005 771 784
37. L.A. Elferink, and V.A. Resto Receptor-tyrosine-kinase-targeted therapies for head and neck cancer J Signal Transduct 2011 982879
38. K. Endo, A. Shirai, M. Furukawa, and T. Yoshizaki Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma Hum Pathol 37 2006 1111 1116
39. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J.O. Park et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
40. S. Fan, Y.X. Ma, J.A. Wang, R.Q. Yuan, Q. Meng, and Y. Cao et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase Oncogene 19 2000 2212 2223
41. S. Fan, J.A. Wang, R.Q. Yuan, S. Rockwell, J. Andres, and A. Zlatapolskiy et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents Oncogene 17 1998 131 141
42. A. Ferlito, M. Partridge, J. Brennan, and H. Hamakawa Lymph node micrometastases in head and neck cancer: a review Acta Otolaryngol 121 2001 660 665
43. A. Ferlito, A.R. Shaha, C.E. Silver, A. Rinaldo, and V. Mondin Incidence and sites of distant metastases from head and neck cancer ORL J Otorhinolaryngol Relat Spec 63 2001 202 207
44. M.B. Ferreira, J.P. Lima, and E.E. Cohen Novel targeted therapies in head and neck cancer Expert Opin Investig Drugs 21 2012 281 295
45. R.L. Ferris, L. Xi, R.R. Seethala, J. Chan, S. Desai, and B. Hoch et al. Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer Clin Cancer Res 17 2011 1858 1866
46. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky Head and neck cancer N Engl J Med 345 2001 1890 1900
47. W. Friedland, H.G. Paretzke, F. Ballarini, A. Ottolenghi, G. Kreth, and C. Cremer First steps towards systems radiation biology studies concerned with DNA and chromosome structure within living cells Radiat Environ Biophys 47 2008 49 61
48. E. Galeazzi, M. Olivero, F.C. Gervasio, A. De Stefani, G. Valente, and P.M. Comoglio et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas Eur Arch Otorhinolaryngol 254 Suppl. 1 1997 S138 S143
49. S.S. Ganapathipillai, M. Medova, D.M. Aebersold, P.W. Manley, S. Berthou, and B. Streit et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51 Cancer Res 68 2008 5769 5777
50. M.M. Gerlach, F. Merz, G. Wichmann, C. Kubick, C. Wittekind, and F. Lordick et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance Br J Cancer 110 2013 479 488
51. P. Ghadjar, W. Blank-Liss, M. Simcock, I. Hegyi, K.T. Beer, and H. Moch et al. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers Clin Exp Metastasis 26 2009 809 815
52. P. Ghadjar, H. Schreiber-Facklam, R. Grater, C. Evers, M. Simcock, and A. Geretschlager et al. Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 76 2010 1127 1132
53. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. Vande Woude Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 2012 89 103
54. M.L. Gillison, G. D'Souza, W. Westra, E. Sugar, W. Xiao, and S. Begum et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers J Natl Cancer Inst 100 2008 407 420
55. S. Giordano Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer Curr Opin Mol Ther 11 2009 448 455
56. S. Giordano, M.F. Di Renzo, R.P. Narsimhan, C.S. Cooper, C. Rosa, and P.M. Comoglio Biosynthesis of the protein encoded by the c-met proto-oncogene Oncogene 4 1989 1383 1388
57. L.L. Gleich, C.M. Collins, P.S. Gartside, J.L. Gluckman, W.L. Barrett, and K.M. Wilson et al. Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 129 2003 26 35
58. M.S. Glickman, and C.L. Sawyers Converting cancer therapies into cures: lessons from infectious diseases Cell 148 2012 1089 1098
59. L. Goetsch, V. Caussanel, and N. Corvaia Biological significance and targeting of c-Met tyrosine kinase receptor in cancer Front Biosci 18 2013 454 473 (Landmark Ed)
60. A. Guo, J. Villen, J. Kornhauser, K.A. Lee, M.P. Stokes, and K. Rikova et al. Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci U S A 105 2008 692 697
61. D.L. Gustafson, B. Frederick, A.L. Merz, and D. Raben Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts Cancer Chemother Pharmacol 61 2008 179 188
62. M. Hanzawa, M. Shindoh, F. Higashino, M. Yasuda, N. Inoue, and K. Hida et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes Carcinogenesis 21 2000 1079 1085
63. S. Hara, K. Nakashiro, S.K. Klosek, T. Ishikawa, S. Shintani, and H. Hamakawa Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells Oral Oncol 42 2006 593 598
64. K.J. Harrington Rash conclusions from a phase 3 study of cetuximab? Lancet Oncol 11 2010 2 3
65. M. Hashibe, P. Brennan, S.C. Chuang, S. Boccia, X. Castellsague, and C. Chen et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium Cancer Epidemiol Biomarkers Prev 18 2009 541 550
66. A. Hashigasako, M. Machide, T. Nakamura, and K. Matsumoto Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor J Biol Chem 279 2004 26445 26452
67. S. Hiscox, and W.G. Jiang Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells Biochem Biophys Res Commun 261 1999 406 411
68. C. Holz, F. Niehr, M. Boyko, T. Hristozova, L. Distel, and V. Budach et al. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells Radiother Oncol 101 2011 158 164
69. G.F. Huber, L. Zullig, A. Soltermann, M. Roessle, N. Graf, and S.K. Haerle et al. Down regulation of E-cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx BMC Cancer 11 217 2011 211 218
70. C.G. Huh, V.M. Factor, A. Sanchez, K. Uchida, E.A. Conner, and S.S. Thorgeirsson Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair Proc Natl Acad Sci U S A 101 2004 4477 4482
71. M. Jeffers, G.A. Taylor, K.M. Weidner, S. Omura, and G.F. Vande Woude Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway Mol Cell Biol 17 1997 799 808
72. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Investig 119 2009 1420 1428
73. A. Kikuchi, H. Yamamoto, and A. Sato Selective activation mechanisms of Wnt signaling pathways Trends Cell Biol 19 2009 119 129
74. C.H. Kim, J. Kim, H. Kahng, and E.C. Choi Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma Ann Surg Oncol 14 2007 1565 1574
75. C.H. Kim, Y.W. Koh, J.H. Han, J.W. Kim, J.S. Lee, and S.J. Baek et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma Head Neck 32 2010 1655 1664
76. C.H. Kim, J.S. Lee, S.O. Kang, J.H. Bae, S.P. Hong, and H. Kahng Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma Oral Oncol 43 2007 1021 1025
77. C.H. Kim, S.K. Moon, J.H. Bae, J.H. Lee, J.H. Han, and K. Kim et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma Acta Otolaryngol 126 2006 88 94
78. W.P. Kloosterman, and R.H. Plasterk The diverse functions of microRNAs in animal development and disease Dev Cell 11 2006 441 450
79. L.M. Knowles, L.P. Stabile, A.M. Egloff, M.E. Rothstein, S.M. Thomas, and C.T. Gubish et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer Clin Cancer Res 15 2009 3740 3750
80. L.P. Kowalski, and A.L. Carvalho Natural history of untreated head and neck cancer Eur J Cancer 36 2000 1032 1037
81. S. Krishnaswamy, R. Kanteti, J.S. Duke-Cohan, S. Loganathan, W. Liu, and P.C. Ma et al. Ethnic differences and functional analysis of MET mutations in lung cancer Clin Cancer Res 15 2009 5714 5723
82. K.A. Kurtz, H.T. Hoffman, M.B. Zimmerman, and R.A. Robinson Decreased E-cadherin but not beta-catenin expression is associated with vascular invasion and decreased survival in head and neck squamous carcinomas Otolaryngol Head Neck Surg 134 2006 142 146
83. P.C. Lau, and A.T. Chan Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway Anti-Cancer Drugs 22 2011 665 673
84. Q.T. Le, R. Fisher, K.S. Oliner, R.J. Young, H. Cao, and C. Kong et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer Clin Cancer Res 18 2012 1798 1807
85. J.H. Lee, S.U. Han, H. Cho, B. Jennings, B. Gerrard, and M. Dean et al. A novel germ line juxtamembrane Met mutation in human gastric cancer Oncogene 19 2000 4947 4953
86. C.R. Leemans, B.J. Braakhuis, and R.H. Brakenhoff The molecular biology of head and neck cancer Nat Rev Cancer 11 2011 9 22
87. C.R. Leemans, R. Tiwari, J.J. Nauta, I. van der Waal, and G.B. Snow Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma Cancer 71 1993 452 456
88. X. Leon, M. Quer, C. Orus, M. del Prado Venegas, and M. Lopez Distant metastases in head and neck cancer patients who achieved loco-regional control Head Neck 22 2000 680 686
89. Y.C. Lim, J.H. Han, H.J. Kang, Y.S. Kim, B.H. Lee, and E.C. Choi et al. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma Oral Oncol 48 2012 1114 1119
90. Y.C. Lim, H.Y. Park, H.S. Hwang, S.U. Kang, J.H. Pyun, and M.H. Lee et al. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells Cancer Lett 271 2008 140 152
91. X. Liu, R.C. Newton, and P.A. Scherle Developing c-MET pathway inhibitors for cancer therapy: progress and challenges Trends Mol Med 16 2010 37 45
92. L. Lo Muzio, A. Farina, C. Rubini, E. Coccia, M. Capogreco, and G. Colella et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma Tumour Biol 27 2006 115 121
93. L. Lo Muzio, R. Leonardi, M.D. Mignogna, G. Pannone, C. Rubini, and T. Pieramici et al. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma Anticancer Res 24 2004 1063 1069
94. H. Lu, K. Liang, Y. Lu, and Z. Fan The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1alpha Cancer Lett 322 2012 78 85
95. P.C. Ma, T. Kijima, G. Maulik, E.A. Fox, M. Sattler, and J.D. Griffin et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions Cancer Res 63 2003 6272 6281
96. P.C. Ma, M.S. Tretiakova, A.C. MacKinnon, N. Ramnath, C. Johnson, and S. Dietrich et al. Expression and mutational analysis of MET in human solid cancers Gene Chromosome Cancer 47 2008 1025 1037
97. M. Machide, A. Hashigasako, K. Matsumoto, and T. Nakamura Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase J Biol Chem 281 2006 8765 8772
98. M. Machtay, J. Moughan, A. Trotti, A.S. Garden, R.S. Weber, and J.S. Cooper et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 2008 3582 3589
99. M. Majem, R. Mesia, M. Manos, J. Gomez, R. Galiana, and F. Cardenal et al. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma Laryngoscope 116 2006 1651 1656
100. C.R. Maroun, and T. Rowlands The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance Pharmacol Ther 142 2013 316 338
101. G. Maulik, A. Shrikhande, T. Kijima, P.C. Ma, P.T. Morrison, and R. Salgia Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev 13 2002 41 59
102. M. Medova, D.M. Aebersold, W. Blank-Liss, B. Streit, M. Medo, and S. Aebi et al. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest Genes Cancer 1 2010 1053 1062
103. M. Medova, D.M. Aebersold, and Y. Zimmer MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks Int J Cancer 130 2012 728 734
104. M. Medova, D.M. Aebersold, and Y. Zimmer The molecular crosstalk between the MET receptor tyrosine kinase and the DNA damage response-biological and clinical aspects Cancers 6 2013 1 27 (Basel)
105. M. Medová, B. Pochon, B. Streit, W. Blank-Liss, P. Francica, and D. Stroka et al. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants Mol Cancer Ther 11 2013 2415 2424
106. W.M. Mendenhall, R.W. Hinerman, R.S. Malyapa, J.W. Werning, R.J. Amdur, and D.B. Villaret et al. Inverted papilloma of the nasal cavity and paranasal sinuses Am J Clin Oncol 30 2007 560 563
107. L. Milas, Z. Fan, N.H. Andratschke, and K.K. Ang Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies Int J Radiat Oncol Biol Phys 58 2004 966 971
108. A.A. Molinolo, P. Amornphimoltham, C.H. Squarize, R.M. Castilho, V. Patel, and J.S. Gutkind Dysregulated molecular networks in head and neck carcinogenesis Oral Oncol 45 2009 324 334
109. S.P. Monga, W.M. Mars, P. Pediaditakis, A. Bell, K. Mule, and W.C. Bowen et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes Cancer Res 62 2002 2064 2071
110. S. Morello, M. Olivero, M. Aimetti, M. Bernardi, S. Berrone, and M.F. Di Renzo et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas J Cell Physiol 189 2001 285 290
111. M. Murai, X. Shen, L. Huang, W.M. Carpenter, C.S. Lin, and S. Silverman et al. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion Int J Oncol 25 2004 831 840
112. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
113. S.L. Organ, and M.S. Tsao An overview of the c-MET signaling pathway Ther Adv Med Oncol 3 2011 S7 S19
114. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
115. H.L. Palka, M. Park, and N.K. Tonks Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1 J Biol Chem 278 2003 5728 5735
116. W.S. Park, S.M. Dong, S.Y. Kim, E.Y. Na, M.S. Shin, and J.H. Pi et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas Cancer Res 59 1999 307 310
117. M. Partridge, G. Emilion, S. Pateromichelakis, E. Phillips, and J. Langdon Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions Oral Oncol 33 1997 332 337
118. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
119. P. Peschard, T.M. Fournier, L. Lamorte, M.A. Naujokas, H. Band, and W.Y. Langdon et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein Mol Cell 8 2001 995 1004
120. J.P. Pignon, A. le Maitre, E. Maillard, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
121. M.E. Prince, R. Sivanandan, A. Kaczorowski, G.T. Wolf, M.J. Kaplan, and P. Dalerba et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proc Natl Acad Sci U S A 104 2007 973 978
122. D.I. Pryor, S.V. Porceddu, B.H. Burmeister, A. Guminski, D.B. Thomson, and K. Shepherdson et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer Radiother Oncol 90 2009 172 176
123. C.N. Qian, X. Guo, B. Cao, E.J. Kort, C.C. Lee, and J. Chen et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma Cancer Res 62 2002 589 596
124. A. Rasola, M. Fassetta, F. De Bacco, L. D'Alessandro, D. Gramaglia, and M.F. Di Renzo et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth Oncogene 26 2007 1078 1087
125. T.D. Reeves, E.G. Hill, K.E. Armeson, and M.B. Gillespie Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data Otolaryngol Head Neck Surg 144 2011 676 684
126. T.E. Reznik, Y. Sang, Y. Ma, R. Abounader, E.M. Rosen, and S. Xia et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor Mol Cancer Res 6 2008 139 150
127. V. Sangwan, J. Abella, A. Lai, N. Bertos, M. Stuible, and M.L. Tremblay et al. Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors J Biol Chem 286 2011 45000 45013
128. V. Sangwan, G.N. Paliouras, J.V. Abella, N. Dube, A. Monast, and M.L. Tremblay et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase J Biol Chem 283 2008 34374 34383
129. R. Sankaranarayanan, E. Masuyer, R. Swaminathan, J. Ferlay, and S. Whelan Head and neck cancer: a global perspective on epidemiology and prognosis Anticancer Res 18 1998 4779 4786
130. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, and J.L. Van Laethem et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
131. M. Sawatsubashi, E. Sasatomi, H. Mizokami, O. Tokunaga, and T. Shin Expression of c-Met in laryngeal carcinoma Virchows Arch 432 1998 331 335
132. J.H. Schipper, U.H. Frixen, J. Behrens, A. Unger, K. Jahnke, and W. Birchmeier E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis Cancer Res 51 1991 6328 6337
133. L. Schmidt, F.M. Duh, F. Chen, T. Kishida, G. Glenn, and P. Choyke et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 1997 68 73
134. G. Scita, and P.P. Di Fiore The endocytic matrix Nature 463 2010 464 473
135. T.Y. Seiwert, and E.E. Cohen Targeting angiogenesis in head and neck cancer Semin Oncol 35 2008 274 285
136. T.Y. Seiwert, R. Jagadeeswaran, L. Faoro, V. Janamanchi, V. Nallasura, and M. El Dinali et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma Cancer Res 69 2009 3021 3031
137. T. Seiwert, J. Sarantopoulos, H. Kallender, S. McCallum, H.N. Keer, and G. Blumenschein Jr. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Investig New Drugs 31 2013 417 424
138. B. Sen, S. Peng, B. Saigal, M.D. Williams, and F.M. Johnson Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer Clin Cancer Res 17 2011 514 524
139. L.V. Sequist, and T.J. Lynch EGFR tyrosine kinase inhibitors in lung cancer: an evolving story Annu Rev Med 59 2008 429 442
140. J.M. Shieh, Y.A. Tang, T.H. Yang, C.Y. Chen, H.S. Hsu, and Y.H. Tan et al. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis Int J Med Sci 10 2013 988 994
141. K.R. Singleton, J. Kim, T.K. Hinz, L.A. Marek, M. Casas-Selves, and C. Hatheway et al. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines Mol Pharmacol 83 2013 882 893
142. P.M. Specenier, and J.B. Vermorken Recurrent head and neck cancer: current treatment and future prospects Expert Rev Anticancer Ther 8 2008 375 391
143. D.R. Spigel, M.J. Edelman, T. Mok, K. O'Byrne, L. Paz-Ares, and W. Yu et al. Treatment rationale study design for the metlung trial: a randomized, double-blind phase iii study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer Clin Lung Cancer 13 2012 500 504
144. D.R. Spigel, T.J. Ervin, R.A. Ramlau, D.B. Daniel, J.H. Goldschmidt Jr., and G.R. Blumenschein Jr. et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer J Clin Oncol 31 2013 4105 4114
145. L.P. Stabile, G. He, V.W. Lui, S. Thomas, C. Henry, and C.T. Gubish et al. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met Clin Cancer Res 19 2013 380 392
146. E. Sulpice, S. Ding, B. Muscatelli-Groux, M. Berge, Z.C. Han, and J. Plouet et al. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells Biol Cell 101 2009 525 539
147. S. Sun, and Z. Wang Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis Int J Cancer 129 2011 2337 2348
148. D. Susuki, S. Kimura, S. Naganuma, K. Tsuchiyama, T. Tanaka, and N. Kitamura et al. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma Cancer Sci 102 2011 2164 2171
149. H.K. Tan, R. Giger, A. Auperin, J. Bourhis, F. Janot, and S. Temam Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - stratification for postsalvage survival Head Neck 32 2010 139 147
150. K. Tan, D. Goldstein, P. Crowe, and J.L. Yang Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis J Cancer Res Clin Oncol 139 2013 1795 1805
151. R.J. Toohill, T. Anderson, R.W. Byhardt, J.D. Cox, J.A. Duncavage, and T.W. Grossman et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report Arch Otolaryngol Head Neck Surg 113 1987 758 761
152. S. Trivedi, J. Mattos, W. Gooding, T.E. Godfrey, and R.L. Ferris Correlation of tumor marker expression with nodal disease burden in metastatic head and neck cancer Otolaryngol Head Neck Surg 149 2013 261 268
153. L. Trusolino, A. Bertotti, and P.M. Comoglio MET signalling: principles and functions in development, organ regeneration and cancer Nat Rev Mol Cell Biol 11 2010 834 848
154. D. Uchida, H. Kawamata, F. Omotehara, K. Nakashiro, T. Kimura-Yanagawa, and S. Hino et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance Int J Cancer 93 2001 489 496
155. H. van der Kuip, L. Wohlbold, C. Oetzel, M. Schwab, and W.E. Aulitzky Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases Am J Pharmacogenomics 5 2005 101 112
156. J.B. Vermorken, and P. Specenier Optimal treatment for recurrent/metastatic head and neck cancer Ann Oncol 21 Suppl. 7 2010 vii252 vii261
157. J. Voortman, T. Harada, R.P. Chang, J.K. Killian, M. Suuriniemi, and W.I. Smith et al. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors Curr Pharm Des 19 2013 833 840
158. H. Vorwerk, and C.F. Hess Guidelines for delineation of lymphatic clinical target volumes for high conformal radiotherapy: head and neck region Radiat Oncol 6 2011 97
159. L. Walsh, C. Gillham, M. Dunne, I. Fraser, D. Hollywood, and J. Armstrong et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC) Radiother Oncol 98 2011 38 41
160. B. Wollenberg Implication of stem cells in the biology and therapy of head and neck cancer Laryngo-Rhino-Otologie 90 Suppl. 1 2011 S110 S119
161. C.L. Woodard, C.R. Goodwin, J. Wan, S. Xia, R. Newman, and J. Hu et al. Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling PLoS ONE 8 2013 e72671
162. B. Worden, X.P. Yang, T.L. Lee, L. Bagain, N.T. Yeh, and J.G. Cohen et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma Cancer Res 65 2005 7071 7080
163. L.Q. Xie, L.J. Bian, Z. Li, Y. Li, Z.X. Li, and B. Li Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma Ann Surg Oncol 17 2010 1927 1936
164. H. Xu, L.P. Stabile, C.T. Gubish, W.E. Gooding, J.R. Grandis, and J.M. Siegfried Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells Clin Cancer Res 17 2011 4425 4438
165. Y. Xu, J. Zhou, T.E. Carey, J.B. McHugh, J.J. Voorhees, and G.J. Fisher Receptor-type protein tyrosine phosphatase beta regulates met phosphorylation and function in head and neck squamous cell carcinoma Neoplasia 14 2012 1015 1022
166. N.R. Young, J. Liu, C. Pierce, T.F. Wei, T. Grushko, and O.I. Olopade et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition Mol Oncol 7 2013 359 368
167. O.T. Yucel, A. Sungur, and S. Kaya c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases Otolaryngol Head Neck Surg 130 2004 698 703
168. Q. Zeng, S. Chen, Z. You, F. Yang, T.E. Carey, and D. Saims et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B J Biol Chem 277 2002 25203 25208
169. Z. Zhang, M.S. Filho, and J.E. Nor The biology of head and neck cancer stem cells Oral Oncol 48 2012 1 9
170. Y.W. Zhang, Y. Su, O.V. Volpert, and G.F. Vande Woude Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proc Natl Acad Sci U S A 100 2003 12718 12723
171. Y. Zimmer, A.V. Vaseva, M. Medova, B. Streit, W. Blank-Liss, and R.H. Greiner et al. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274 Cancer Lett 289 2010 228 236